Floatz logo

Tcr Transduced T-Cells

Hematological Neoplasms

National Cancer Institute (NCI)Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

116 Active assets in the Hematological Neoplasms cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
Rasburicase
M.D. Anderson Cancer Center
Phase 4BB
Fludarabine
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Tcr Transduced T-Cells is also rated in:

Gastrointestinal/Genitourinary CancersDormant
CCC
Indicative ·
53 / 100
View asset →
malignant endocrine neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
neuroendocrine neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →